Lipid Metabolism

Lipid Associates at Massachusetts General Hospital diagnoses and treats patients with lipid metabolism disorders and conducts leading-edge research into these conditions.

Outstanding Patient Care at the Lipid Clinic

Contact Us

Lipid Associates
Wang Ambulatory Care Center
15 Parkman Street, Suite 730
Boston, MA 02114

Phone: 617-643-5588

When Mason Freeman, MD, founded Lipid Associates, Mass General’s lipid clinic, in 1985, it was one of the few treatment centers in New England devoted to the care of patients with lipid metabolism disorders. Since these disorders can cause heart attacks, strokes and other serious but common vascular diseases, the clinic quickly became a high referral center.

Our program’s two staff physicians, Dr. Freeman and Sherry Haydock, MD, were involved in some of the earliest studies of statins, new medications that became the dominant therapy for cholesterol disorders. Since 1985, our team has treated thousands of patients with high levels of LDL and other lipid disorders that defy conventional treatment and require therapies other than statins.

Today our clinic continues to serve as a valuable medical resource in the community, providing advanced diagnostics and therapies for people with common and rare lipid disorders.

Learn more about the Lipid Associates, Mass General’s lipid clinic

Groundbreaking Research into Lipid Disorders

Following a longstanding tradition of Mass General’s Endocrine Unit, our specialists pursue a dual mission: to diagnose and treat patients and to study lipid disorders in our Lipid Metabolism Laboratory.

By deepening their knowledge of lipid metabolism at the cellular level, our physician-scientists help improve diagnostics and treatments for rare and complicated lipid disorders.

Our team’s investigations also are instrumental in developing promising new therapies. In addition to managing our research program, Dr. Freeman works closely with the Mass General Center for Computational and Integrative Biology. This center focuses on translating basic-science research into targeted therapies for metabolic disorders, such as diabetes, which increase a patient’s risk of developing atherosclerosis (blocked arteries).